Tuesday, March 07, 2017 9:14:18 PM
"Some regenerative medicine advocates hope the new law will make FDA more receptive to future submissions just by explicitly stating that the accelerated approval should apply to stem cell therapies."
"And though Cures stops short of explicitly removing a requirement for phase III trials, winning accelerated approval can make them unnecessary."
"between 2011 and 2015 found that only 20% relied on phase III data."
http://www.sciencemag.org/news/2016/12/under-21st-century-cures-legislation-stem-cell-advocates-expect-regulatory-shortcuts-0
The posts contained on this account are my own opinions and are not recommendations or advise to buy or sell any security, stocks or other investments. These posts are for entertainment purposes only and are not considered to be facts or truth.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM